Digital biomarkers are collected through quantifiable physiological and behavioral data such as smartphones, wearable or sensors, which are used to monitor health conditions and to assess the progression or treatment response of the disease. These biomarkers provide continuous, exit of clinical settings, real -time insight, which enable individual and preventive healthcare. Digital biomarker market growth is inspired by increasing wearable health techniques, increasing prevalence of chronic and neurological diseases, increasing demand for distant patient monitoring, progression in AI and data analytics and changes towards value-based and accurate drugs.
Key Growth Drivers and Opportunities
Increasing Wearable Health Techniques: Increasing wearable health technologies is a major driver of development in digital biomarkers market, as this equipment enabling physical and practical data such as heart rate, sleep patterns, activity levels and constant, real -time collection of glucose levels. This rich data stream allows for identification and verification of digital biomarkers that can be used to monitor the progression of the disease, detect early signs of health issues and to personalize treatment plans. Since the wearables are more economical, user adapted, and integrate with AI and cloud-based platforms, healthcare providers and researchers get deep, non-invasive insight into the patient’s health, which gives the expansion and diagnostic use of digital biomarkers in a wide range of medical fields.
Challenges
The digital biomarker market faces several borders that can adopt it’s widely adoption and slow down. A major challenge is the lack of standardized verification and regulatory framework, which increases concerns about the accuracy, reliability, and clinical relevance of digital biomarker data. Data privacy and safety risk associated with continuous health monitoring also create significant moral and legal obstacles. Additionally, inequalities in access to digital health technologies, especially in low-resources settings, can limit their global projection. The integration of digital biomarkers in the existing healthcare systems remains complicated due to interoperability issues, and healthcare professionals may require additional training to effectively interpret and implement these data.
Innovation and Expansion
Koneksa Reveals Verified Digital Biomarkers to Promote Research in the Life Sciences
In October 2022, Koneksa, a healthcare technology business that creates digital biomarkers that are confirmed by evidence, announced the opening of its clinical pipeline, which includes biomarkers from therapeutic areas such as brain, cancer, and respiratory. The business is developing 15 digital biomarker programs and will soon begin a number of clinical investigations. More than 20 peer-reviewed publications have been published by Koneksa and associates.
Koneksa’s digital biomarker platform converts traditionally analog procedures into digital ones by using algorithms to evaluate and incorporate real-time patient data into clinical trials. Koneksa’s biomarker technology has the potential to improve accuracy and capture a more comprehensive dataset by creating a range of validated, evidence-based digital biomarker solutions that can be easily incorporated into clinical studies. These solutions include vital-sign monitoring, at-home spirometry, actigraphy, and tools for tracking gait and balance.
Apple and Biogen Collaborated to Create Digital Biomarkers for Mental Health
In January 2021, in partnership with Apple, Biogen Inc. unveiled a new virtual research project to examine how the iPhone and Apple Watch may be used to track cognitive function and screen for cognitive health deterioration, including mild cognitive impairment (MCI).
Young and old persons with a range of cognitive abilities will be among the participants in the multi-year observational research project, which will begin later in 2021. With the use of Biogen’s extensive neuroscience expertise and the potent technology found in the Apple Watch and iPhone, the study’s main goals are to create digital biomarkers that will help track cognitive function over time and spot early indicators of MCI.
Inventive Sparks, Expanding Markets
Digital biomarker companies grow by taking advantage of AI for data insights, partnership with pharma and tech firms, validate products for regulatory approval, integrated to wear, focuses on chronic diseases, and data security and health system ensures compatibility.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
